We report on two cases of severe recurrent respiratory papillomatosis (RRP) involvement
where the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab IV has …

Objectives: We review and report the use of high-dose bevacizumab for the treatment of
recurrent respiratory papillomatosis (RRP) in pediatric patients. Methods: We included all …

Objective: Recurrent respiratory papillomatosis (RRP) is caused by types 6 and 11 human
papilloma virus and occurs in both children and adults. It is characterized by proliferation of …

Purpose Recent approaches for recurrent respiratory papillomatosis including local injection
of bevacizumab and HPV vaccination show promise in reducing the need for frequent …

Abstract Recurrent Respiratory Papillomatosis (RRP) is a benign disease of the airway that
can result in symptoms ranging from mild dysphonia to respiratory distress to respiratory …

Objectives (1) To systematically identify studies evaluating the use of intralesional cidofovir
or bevacizumab as an adjunct in adult recurrent respiratory papillomatosis, determine …

Background Specific HPV types cause recurrent respiratory papillomatosis (RRP). When
administered intralesionally, cidofovir, an antiviral agent, has shown favorable outcomes in …

Background: Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that is
used off-label for select cases of recurrent respiratory papillomatosis (RRP) that are severe …

Recurrent respiratory papillomatosis (RRP) is a rare disease characterized by recurrent
papilloma along the aerodigestive tract. In this case, we describe a 16‐year‐old with …

Background: Respiratory papillomatosis is one of the common benign lesions of the airway
that is often difficult to treat and carries significant morbidity. Bevacizumab is a monoclonal …